[{"image_source": "https://textbook-images-19283761293.s3.amazonaws.com/neuroscience/00291.jpeg", "image_caption": "<figcaption class=\"figleg\"><a class=\"calibre5\" id=\"ca0010\"></a><span class=\"fignum\">Fig. 13.1</span> <a class=\"calibre5\" id=\"sp0010\"></a>Features of idiopathic Parkinson's disease.<br class=\"calibre7\"/><a class=\"calibre5\" id=\"sp0015\"></a>The combination of a flexed posture, slow shuffling gait, mask-like facial expression and unilateral tremor is highly characteristic.</figcaption>"}, {"image_source": "https://textbook-images-19283761293.s3.amazonaws.com/neuroscience/00292.jpeg", "image_caption": "<figcaption class=\"figleg\"><a class=\"calibre5\" id=\"ca0015\"></a><span class=\"fignum\">Fig. 13.2</span> <a class=\"calibre5\" id=\"sp0020\"></a>Tremor in Parkinson's disease.<br class=\"calibre7\"/><a class=\"calibre5\" id=\"sp0025\"></a>The presence of a coarse, low-frequency \u2018pill-rolling\u2019 rest tremor (illustrated here) is virtually diagnostic of idiopathic Parkinson's disease. Tremor is often embarrassing for the patient and may be difficult to treat.</figcaption>"}, {"image_source": "https://textbook-images-19283761293.s3.amazonaws.com/neuroscience/00293.jpeg", "image_caption": "<figcaption class=\"figleg\"><a class=\"calibre5\" id=\"ca0020\"></a><span class=\"fignum\">Fig. 13.3</span> <a class=\"calibre5\" id=\"sp0030\"></a>Functional imaging of dopamine transport in Parkinson's disease.<br class=\"calibre7\"/><a class=\"calibre5\" id=\"sp0035\"></a><strong class=\"calibre8\">(A)</strong> Axial section through the basal ganglia showing the normal pattern of uptake in a healthy control. The characteristic \u2018comma\u2019 shape of the striatum (caudate nucleus and putamen) is seen; <strong class=\"calibre8\">(B)</strong> In a patient with Parkinson's disease, there is markedly reduced signal in the putamen but not in the head of the caudate nucleus, creating a \u2018full stop\u2019 appearance. [Images obtained using single photon emission computed tomography (SPECT) with the radioactively labelled (<sup class=\"calibre14\">123</sup>I) beta-CIT.] <span class=\"figcredit\">From Seibyl, JP: Single-photon emission computed tomography and positron emission tomography evaluations of patients with central motor disorders. J Semin Nuclear Med (2008) with permission.</span></figcaption>"}, {"image_source": "https://textbook-images-19283761293.s3.amazonaws.com/neuroscience/00294.jpeg", "image_caption": "<figcaption class=\"figleg\"><a class=\"calibre5\" id=\"ca0025\"></a><span class=\"fignum\">Fig. 13.4</span> <a class=\"calibre5\" id=\"sp0040\"></a>Comparison of idiopathic Parkinson's disease (IPD) and progressive supranuclear palsy (PSP).<br class=\"calibre7\"/><a class=\"calibre5\" id=\"sp0045\"></a>The main clinical features including response to dopamine replacement therapy (L-DOPA) are compared in <strong class=\"calibre8\">(A)</strong> and the characteristically erect posture seen in PSP is illustrated in <strong class=\"calibre8\">(B)</strong>.</figcaption>"}, {"image_source": "https://textbook-images-19283761293.s3.amazonaws.com/neuroscience/00293.jpeg", "image_caption": "<figcaption class=\"figleg\"><a class=\"calibre5\" id=\"ca0030\"></a><span class=\"fignum\">Fig. 13.5</span> <a class=\"calibre5\" id=\"sp0050\"></a>Degeneration of the substantia nigra in Parkinson's disease.<br class=\"calibre7\"/><a class=\"calibre5\" id=\"sp0055\"></a><strong class=\"calibre8\">(A)</strong> Normal midbrain (in cross section) with a deeply pigmented substantia nigra; <strong class=\"calibre8\">(B)</strong> Pallor of the substantia nigra in a case of Parkinson's disease. <span class=\"figcredit\">From Kumar et\u202fal: Robbins and Cotran's Pathologic Basis of Disease 7e (Saunders 2004) with permission.</span></figcaption>"}, {"image_source": "https://textbook-images-19283761293.s3.amazonaws.com/neuroscience/00295.jpeg", "image_caption": "<figcaption class=\"figleg\"><a class=\"calibre5\" id=\"ca0035\"></a><span class=\"fignum\">Fig. 13.6</span> <a class=\"calibre5\" id=\"sp0060\"></a>Lewy bodies.<br class=\"calibre7\"/><a class=\"calibre5\" id=\"sp0065\"></a><strong class=\"calibre8\">(A)</strong> On routine haematoxylin and eosin (H&amp;E)-stained sections Lewy bodies appear as bright pink structures in the neuronal cytoplasm, surrounded by a pale halo; <strong class=\"calibre8\">(B)</strong> They can also be demonstrated by immunohistochemistry for alpha-synuclein protein, which is the main constituent. <span class=\"figcredit\">Courtesy of Professor Steve Gentleman.</span></figcaption>"}, {"image_source": "https://textbook-images-19283761293.s3.amazonaws.com/neuroscience/00296.jpeg", "image_caption": "<figcaption class=\"figleg\"><a class=\"calibre5\" id=\"ca0040\"></a><span class=\"fignum\">Fig. 13.7</span> <a class=\"calibre5\" id=\"sp0070\"></a>Progression of Lewy body pathology.<br class=\"calibre7\"/><a class=\"calibre5\" id=\"sp0075\"></a>Lewy bodies first appear in the medulla and olfactory bulb and then progressively spread to the pons, midbrain, limbic lobe and neocortex. Key anatomical structures involved in each of the six Braak stages are indicated and disease progression is colour-coded on the inferior and midsagittal views of the cerebral hemisphere. <span class=\"figcredit\">Modified from Braak H et\u202fal: Neurobiology of Aging 24 (2003) with permission.</span></figcaption>"}, {"image_source": "https://textbook-images-19283761293.s3.amazonaws.com/neuroscience/00297.jpeg", "image_caption": "<figcaption class=\"figleg\"><a class=\"calibre5\" id=\"ca0045\"></a><span class=\"fignum\">Fig. 13.8</span> <a class=\"calibre5\" id=\"sp0080\"></a>Synucleinopathies such as Parkinson's disease and multiple system atrophy (MSA) are characterized by pathological neuronal and glial inclusions composed of alpha-synuclein protein.<br class=\"calibre7\"/><a class=\"calibre5\" id=\"sp0085\"></a>This microscopic image shows glial cytoplasmic inclusions (GCIs) within oligodendrocytes in a case of MSA, highlighted by immunohistochemistry (antibody labelling). <span class=\"figcredit\">Courtesy of Professor Steve Gentleman.</span></figcaption>"}, {"image_source": "https://textbook-images-19283761293.s3.amazonaws.com/neuroscience/00298.jpeg", "image_caption": "<figcaption class=\"figleg\"><a class=\"calibre5\" id=\"ca0050\"></a><span class=\"fignum\">Fig. 13.9</span> <a class=\"calibre5\" id=\"sp0090\"></a>Genes involved in familial Parkinson's disease.<br class=\"calibre7\"/><a class=\"calibre5\" id=\"sp0095\"></a>Around a dozen genes have been identified in association with familial Parkinson's disease, but the six best understood are illustrated. In each case the different names for the genes are shown above the protein encoded.</figcaption>"}, {"image_source": "https://textbook-images-19283761293.s3.amazonaws.com/neuroscience/00299.jpeg", "image_caption": "<figcaption class=\"figleg\"><a class=\"calibre5\" id=\"ca0055\"></a><span class=\"fignum\">Fig. 13.10</span> <a class=\"calibre5\" id=\"sp0100\"></a>Treatment of Parkinson's disease.<br class=\"calibre7\"/><a class=\"calibre5\" id=\"sp0105\"></a><strong class=\"calibre8\">(A)</strong> Several agents used in the symptomatic treatment of Parkinson's disease act at the dopaminergic synapse, affecting dopamine synthesis, release, reuptake or metabolism. A number of dopamine receptor agonists are also available which act directly at post-synaptic dopamine receptors in the striatum; <strong class=\"calibre8\">(B)</strong> The two main pathways for enzymic degradation of dopamine are shown, via monoamine oxidase (MAO) and catechol-ortho-methyltransferase (COMT). MAO/COMT inhibitors are also used in Parkinson's disease to increase availability of dopamine.</figcaption>"}, {"image_source": "https://textbook-images-19283761293.s3.amazonaws.com/neuroscience/00300.jpeg", "image_caption": "<figcaption class=\"figleg\"><a class=\"calibre5\" id=\"ca0060\"></a><span class=\"fignum\">Fig. 13.11</span> <a class=\"calibre5\" id=\"sp0110\"></a>Surgery in Parkinson's disease.<br class=\"calibre7\"/><a class=\"calibre5\" id=\"sp0115\"></a>Intraoperative photograph of a patient wearing a stereotactic frame undergoing functional neurosurgery for drug-resistant Parkinson's disease. <span class=\"figcredit\">From Larson, PS: Neurosurg Clin North Am 2010; 21(4): 691\u2013698, with permission.</span></figcaption>"}, {"image_source": "https://textbook-images-19283761293.s3.amazonaws.com/neuroscience/00301.jpeg", "image_caption": "<figcaption class=\"figleg\"><a class=\"calibre5\" id=\"ca0065\"></a><span class=\"fignum\">Fig. 13.12</span> <a class=\"calibre5\" id=\"sp0120\"></a>The subthalamic nucleus (STN) is an important target for deep brain stimulation in Parkinson's disease.<br class=\"calibre7\"/><a class=\"calibre5\" id=\"sp0125\"></a>This small, lens-shaped nucleus belongs to the basal ganglia. It lies just below the thalamus, close to the substantia nigra and posterior limb of the internal capsule.</figcaption>"}, {"image_source": "https://textbook-images-19283761293.s3.amazonaws.com/neuroscience/00302.jpeg", "image_caption": "<figcaption class=\"figleg\"><a class=\"calibre5\" id=\"ca0070\"></a><span class=\"fignum\">Fig. 13.13</span> <a class=\"calibre5\" id=\"sp0130\"></a>Voluntary motor loop of the basal ganglia.<br class=\"calibre7\"/><a class=\"calibre5\" id=\"sp0135\"></a>The central, \u2018closed loop\u2019 component originates and terminates in the supplementary motor area (SMA) in the medial frontal lobe (see <a class=\"calibre5\" href=\"part0008.html#c00003\">Ch. 3</a>, <a class=\"calibre5\" href=\"part0008.html#f0025\">Fig. 3.4b</a>). Other sensory and motor areas form \u2018open-loop\u2019 components.</figcaption>"}, {"image_source": "https://textbook-images-19283761293.s3.amazonaws.com/neuroscience/00303.jpeg", "image_caption": "<figcaption class=\"figleg\"><a class=\"calibre5\" id=\"ca0075\"></a><span class=\"fignum\">Fig. 13.14</span> <a class=\"calibre5\" id=\"sp0140\"></a>Medium spiny neurons in the striatum.<br class=\"calibre7\"/><a class=\"calibre5\" id=\"sp0145\"></a><strong class=\"calibre8\">(A)</strong> Approximately 95% of basal ganglia neurons are classified as \u2018medium spiny\u2019 cells. Several medium spiny striatal neurons are illustrated in the figure: some projecting to the external pallidum, others projecting to the internal pallidum. These two types of neuron belong to the \u2018indirect\u2019 and \u2018direct\u2019 pathways, respectively [see text for further discussion]; <strong class=\"calibre8\">(B)</strong> Medium spiny neurons in the striatum (caudate nucleus/putamen) receive excitatory projections from the frontal lobe. These excitatory cortico-striatal projections terminate on the heads of dendritic spines. In contrast, dopaminergic projections (from the substantia nigra) synapse on the shafts of dendritic spines, facilitating direct pathway neurons but inhibiting those belonging to the indirect pathway.</figcaption>"}, {"image_source": "https://textbook-images-19283761293.s3.amazonaws.com/neuroscience/00293.jpeg", "image_caption": "<figcaption class=\"figleg\"><a class=\"calibre5\" id=\"ca0080\"></a><span class=\"fignum\">Fig. 13.15</span> <a class=\"calibre5\" id=\"sp0150\"></a>The output of the basal ganglia is inhibitory.<br class=\"calibre7\"/><a class=\"calibre5\" id=\"sp0155\"></a>This simplified diagram illustrates the \u2018default\u2019 state of the basal ganglia. The internal pallidum is tonically active and powerfully inhibits nuclei in the ventral thalamus, blocking activity in thalamocortical projections that take part in basal ganglia loops. The subthalamic nucleus (which belongs to the basal ganglia) is constantly active and excites the internal pallidum, reinforcing its restraining action on the thalamus. (If the internal pallidum is a \u2018brake\u2019, then the subthalamic nucleus is a \u2018foot\u2019 on the brake pedal.)</figcaption>"}, {"image_source": "https://textbook-images-19283761293.s3.amazonaws.com/neuroscience/00293.jpeg", "image_caption": "<figcaption class=\"figleg\"><a class=\"calibre5\" id=\"ca0085\"></a><span class=\"fignum\">Fig. 13.16</span> <a class=\"calibre5\" id=\"sp0160\"></a>Dopamine receptor subtypes.<br class=\"calibre7\"/><a class=\"calibre5\" id=\"sp0165\"></a>There are two major subtypes of dopamine receptor. D1-like receptors (D1, D5) are excitatory, whereas D2-like receptors (D2, D3, D4) are inhibitory.</figcaption>"}, {"image_source": "https://textbook-images-19283761293.s3.amazonaws.com/neuroscience/00293.jpeg", "image_caption": "<figcaption class=\"figleg\"><a class=\"calibre5\" id=\"ca0090\"></a><span class=\"fignum\">Fig. 13.17</span> <a class=\"calibre5\" id=\"sp0170\"></a>The effect of dopamine on a striatal medium spiny neuron depends on the type of dopamine receptor that it expresses.<br class=\"calibre7\"/><a class=\"calibre5\" id=\"sp0175\"></a>Neurons that are part of the direct pathway express D1-like dopamine receptors and are excited by dopamine. Neurons that are part of the indirect pathway express D2-like dopamine receptors and are inhibited by dopamine. Dopamine therefore shifts the balance of activity in favour of the direct pathway.</figcaption>"}, {"image_source": "https://textbook-images-19283761293.s3.amazonaws.com/neuroscience/00304.jpeg", "image_caption": "<figcaption class=\"figleg\"><a class=\"calibre5\" id=\"ca0095\"></a><span class=\"fignum\">Fig. 13.18</span> <a class=\"calibre5\" id=\"sp0180\"></a>The connections of the basal ganglia work by inhibition and disinhibition.<br class=\"calibre7\"/><a class=\"calibre5\" id=\"sp0185\"></a><strong class=\"calibre8\">(A)</strong> Simple illustration of an inhibitory interaction between two nerve cells. Activity in the excitatory neuron (red) is inhibited by an inhibitory interneuron (blue); <strong class=\"calibre8\">(B)</strong> Disinhibition (release of inhibition) occurs when two inhibitory neurons occur in sequence. In this case the excitatory neuron (red) has been released from inhibition (or \u2018disinhibited\u2019) as the neuron that was previously restraining its action has itself been inhibited. In functional terms, disinhibition is equivalent to excitation.</figcaption>"}, {"image_source": "https://textbook-images-19283761293.s3.amazonaws.com/neuroscience/00305.jpeg", "image_caption": "<figcaption class=\"figleg\"><a class=\"calibre5\" id=\"ca0100\"></a><span class=\"fignum\">Fig. 13.19</span> <a class=\"calibre5\" id=\"sp0190\"></a>Direct and indirect pathways of the basal ganglia.<br class=\"calibre7\"/><a class=\"calibre5\" id=\"sp0195\"></a><strong class=\"calibre8\">(A)</strong> Striatal neurons belonging to the direct pathway project directly to the internal pallidum and inhibit it, thereby releasing thalamocortical neurons from inhibition. In the voluntary motor loop, the direct pathway therefore facilitates movement; <strong class=\"calibre8\">(B)</strong> Striatal neurons belonging to the indirect pathway project to the external pallidum, where they inhibit a group of neurons that would normally reduce the firing rate of the subthalamic nucleus. This means that the indirect pathway disinhibits the subthalamic nucleus and accentuates its excitation of the internal pallidum. The indirect pathway therefore reinforces the default (inhibitory) outflow of the basal ganglia and prevents unwanted movements.</figcaption>"}, {"image_source": "https://textbook-images-19283761293.s3.amazonaws.com/neuroscience/00306.jpeg", "image_caption": "<figcaption class=\"figleg\"><a class=\"calibre5\" id=\"ca0105\"></a><span class=\"fignum\">Fig. 13.20</span> <a class=\"calibre5\" id=\"sp0200\"></a>Huntington's disease.<br class=\"calibre7\"/><a class=\"calibre5\" id=\"sp0205\"></a>Post-mortem examination of the brain in an individual with Huntington\u2019s disease [right] compared to a normal control brain [left] shows marked cortical thinning, extensive loss of subcortical white matter and dilation of the lateral ventricle. There is also striking atrophy of the caudate nucleus (labelled \u201cCN\u201d in the normal control brain) which takes part in basal ganglia loops passing through the prefrontal cortex that are concerned with cognition and behaviour. <span class=\"figcredit\">From Kumar et\u202fal.: Robbins and Cotran's Pathologic Basis of Disease 7e (Saunders 2004) with permission.</span></figcaption>"}, {"image_source": "https://textbook-images-19283761293.s3.amazonaws.com/neuroscience/00293.jpeg", "image_caption": "<figcaption class=\"figleg\"><a class=\"calibre5\" id=\"ca0110\"></a><span class=\"fignum\">Fig. 13.21</span> <a class=\"calibre5\" id=\"sp0210\"></a>MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine).<br class=\"calibre7\"/><a class=\"calibre5\" id=\"sp0215\"></a><strong class=\"calibre8\">(A)</strong> MPTP is converted to the neurotoxic agent MPP+ by monoamine oxidase B. MPP+ is then taken up by dopaminergic neurons; <strong class=\"calibre8\">(B)</strong> MPP+ is structurally similar to the neurotoxic herbicide paraquat.</figcaption>"}, {"image_source": "https://textbook-images-19283761293.s3.amazonaws.com/neuroscience/00307.jpeg", "image_caption": "<figcaption class=\"figleg\"><a class=\"calibre5\" id=\"ca0115\"></a><span class=\"fignum\">Fig. 13.22</span> <a class=\"calibre5\" id=\"sp0220\"></a>Pathogenetic factors in idiopathic Parkinson's disease.<br class=\"calibre7\"/><a class=\"calibre5\" id=\"sp0225\"></a>Interaction between the three main factors creates a vicious cycle in dopaminergic neurons (ROS = reactive oxygen species).</figcaption>"}]